ARWR - GSK inks $1B deal to obtain rights to hepatitis B drug from J&J
2023-10-31 10:31:16 ET
More on Arrowhead Pharma
- Arrowhead Pharmaceuticals: A High-Risk, High-Reward Bet
- Arrowhead Remains Well-Positioned For RNAi-Based Therapeutic Breakthroughs
- Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2023 Earnings Call Transcript
- Ionis late-stage rare disease data fails to impress Bernstein
- Seeking Alpha’s Quant Rating on Arrowhead Pharmaceuticals
For further details see:
GSK inks $1B deal to obtain rights to hepatitis B drug from J&J